Objective. To evaluate the pharmacokinetic, safety, and effectiveness data of dosing low-molecular-weight heparins (LMWHs) for prophylaxis of venous thromboembolic events (VTEs) in obese people. Data Sources. A PubMed search (1966( to September 2015 was performed of published English articles using the following keywords: low-molecular-weight heparin, prophylaxis, and obesity. Study Selection and Data Extraction. In all, a total of 11 articles were included in this review. The search was conducted to identify pharmacokinetic studies, clinical trials (phases I-IV), or retrospective evaluations of the impact of weight and/or obesity on anti-Xa levels as well as the safety and effectiveness of LMWHs used for VTE prophylaxis. Data Synthesis. The vast majority of the available data focus on enoxaparin. Pharmacokinetic, effectiveness, and safety data all support increased enoxaparin dosing in obese patients. However, the optimal adjustment remains uncertain. For now, we recommend using 40 mg twice daily as the data for effectiveness use this regimen. Dalteparin dosing should not be adjusted in class I-II obese (body mass index 30.0-39.9 kg/m 2 ) patients. Data regarding the impact of class III obesity (body mass index ≥40 kg/m 2 ) on dalteparin effectiveness is needed. Total body weight dosing of tinzaparin can be used to optimize anti-Xa levels, but safety and effectiveness data are needed before weight-based tinzaparin dosing is routine medical practice for obese patients. Conclusions. The data regarding dosing of LMWHs for VTE prophylaxis are quite limited. High-quality studies are needed to help optimize dosing for obese adults requiring LMWH prophylaxis.
Introduction
The American College of Chest Physicians (ACCP) recommends prophylaxis of venous thromboembolic events (VTEs) for patients at risk. 1 Patient populations at risk include those who are ≥60 years of age, are taking an estrogen-containing medication, or have a history of VTE, recent surgery, paralysis, obesity, heart failure, or recent trauma. With an estimated of 1 million cases of VTE and over 200 000 deaths annually in the United States, VTE remains a major cause of morbidity and mortality despite the recognition of patients at risk and guidelines for the implementation of prophylactic therapy. 1, 2 The ACCP guidelines recommend fixed doses of LMWH prophylaxis in patients who are at risk for VTEs. Few obese patients were included in the trials supporting fixed dosing of LMWH for prophylaxis and LMWH use has been understudied in the obese population. Therefore, it is unknown whether the ACCP guideline recommendation will produce the desired anticoagulation, safety, and effectiveness in obese persons. 1 This is paramount importance in the United States as 1 in 3 adults are obese and obesity is a risk factor for VTE. 3 The risk for VTE in obese patients is estimated at twice that of nonobese patients, 5 times as likely in patients less than 40 years old, and 6 times as likely in patients with a body mass index (BMI) greater than 35 kg/m 2 or higher. 4 Many studies since the 1960s have shown that increased body weight has a linear relationship with the risk of VTE. 5 A large prospective cohort study of female nurses reported a strong correlation between total body weight and risk for pulmonary embolism. 6 Specifically, every 1 kg/m 2 increase of BMI was associated with an increased risk of pulmonary The pharmacokinetic changes within the obese population include an increased volume of distribution of lipophilic drugs, reduced tissue perfusion, change in hepatic and renal clearance of drugs, and change in elimination half-life. 7 Compared with unfractionated heparin, LMWHs have improved bioavailability, dose-dependent clearance, and increased half-life. 8 These characteristics of LMWH create more predictable anticoagulation response 8 ; however, in the obese population, alterations in pharmacokinetics within an obese patient may necessitate specialized dosing for appropriate the anticoagulation effect.
Current dosing strategies for obese patients include use of product labeling, empiric dose adjustments, and/or adjustment based on anti-factor Xa (anti-Xa) levels as shown in clinical trials. Product labeling for the prophylaxis of VTE does not specifically recommend dosing enoxaparin, dalteparin, or tinzaparin differently in obese patients than in nonobese patients. [9] [10] [11] For nonobese patients, prophylaxis of VTE with enoxaparin should be dosed at 30 mg subcutaneously Q12H or 40 mg Q24H, dalteparin 2500 IU/ kg or 5000 IU/kg subcutaneously once daily. Tinzaparin is not approved for prophylaxis, but dosing regimens of 50 anti-Xa units/kg 2 hours preoperatively followed by 50 anti-Xa units/kg once daily or 75 anti-Xa units/kg once daily have been used. [9] [10] [11] [12] Anti-factor Xa monitoring is not recommended on a routine basis in clinically stable adults, but may be useful in clinical situations such as obesity. 13 Evidence suggests peak anti-Xa levels 4 hours after subcutaneous injection should be measured with therapeutic levels of 0.4 to 1.1 IU/mL for treatment of VTE using twice daily dosing and 1.0 to 2.0 IU/mL for once daily dosing. Formal dosing protocols were used by 81% of 207 hospitals according to an international survey of directors of pharmacy or medical information pharmacists from Australia, New Zealand, the United Kingdom, and the United States. 14 Almost all of the protocols used (96%) did not adhere to the product labeling, with renal function (87%) and weight (62%) being the factors most commonly linked to label nonadherence. Only 23% of hospitals surveyed used anti-Xa monitoring after the LMWH dose.
Three VTE prophylaxis strategies were evaluated for safety and effectiveness in an observational cohort study in bariatric surgery patients. 15 LMWH or unfractionated heparin (UFH) treatment preoperatively and postoperatively were compared with treatment categories of UFH/UFH (n = 4402; number of BMI >60 kg/m 2 = 9), UFH/LMWH (n = 4482; number of BMI >60 kg/m 2 = 10), and LMWH/ LMWH (n = 15 891; number of BMI >60 kg/m 2 = 9), with the primary outcome of rates of VTE, hemorrhage, or serious hemorrhage within 30 days of surgery. Rates of VTE were 57% lower in the UFH/LMWH group (odds ratio [OR] = 0.43; 95% CI = 0.21-0.91, P = .03) and 66% lower in the LMWH/LMWH group (OR = 0.34; 95% CI = 0.19-0.62; P < .001) compared with the UFH/UFH group, without statistically significant rates of hemorrhage among the groups. In summary, LMWH was more statistically effective than UFH for postoperative prevention of VTE.
It is important to have data regarding the pharmacokinetics, effectiveness, and safety of LMWH dosing regimens used in obese patients given the narrow therapeutic window of these agents. This review will critically evaluate the currently available data as well as provide recommendations for dosing and future research priorities to ensure optimal VTE prophylaxis in obese patients.
Data Sources
A PubMed search (1966 to September 2015) was performed of published English articles using the following keywords: low-molecular-weight heparin, prophylaxis, and obesity.
LMWH for VTE Prophylaxis in Obese Patients
Enoxaparin Anti-Xa Pharmacokinetics ( Table 1) . Rowan et al compared anti-Xa levels of patients receiving 30 mg every 12 hours (n = 19; mean BMI 48.4 kg/m 2 ) to those receiving 40 mg of enoxaparin every 12 hours (n = 33; mean BMI 48.5 kg/m 2 ) in patients who received laparoscopic gastric bypass or banding. 16 Baseline characteristics included an average age between 40.8 ± 9.1 and 41.7 ± 10.7 years, weight between 135.6 ± 27.9 and 141.6 ± 25.4 kg, and BMI between 48.4 ± 7.1 and 48.5 ± 8.5 kg/m 2 . Anti-Xa levels were obtained 4 hours after the first and third doses, with an appropriate anti-Xa level defined as 0.18 to 0.44 units/mL. After the third dose, more patients receiving enoxaparin 40 mg Q12H reached an appropriate anti-Xa level after those receiving 30 mg Q12H (42% vs 9%; P = .12). Increased enoxaparin dosing for VTE prophylaxis in patients undergoing bariatric surgery may be needed to reach appropriate anti-Xa levels. Further studies of larger sample sizes and longer durations of prophylaxis are needed to confirm these results. From these data, additional studies are needed to evaluate the correlation between LMWH dosing and anti-Xa levels, since doses of enoxaparin greater than 40 mg every 12 hours (Q12H) may be needed. Moreover, in this trial, 58% of patients receiving 40 mg Q12H did not achieve an appropriate anti-Xa level. In conclusion, bariatric surgery patients receiving enoxaparin 40 mg Q12H for prophylaxis had significantly increased anti-Xa levels compared with patients receiving enoxaparin 30 mg Q12H.
Borkgren-Okonek et al conducted an open-labeled
prospective study with 223 patients undergoing bariatric surgery. 17 Baseline characteristics included patients with an average age of 44 years, with average weight of 141 kg, BMI of 50.4 kg/m 2 . Patients with a BMI ≤50 kg/m 2 (n = 124, average BMI 44.9 kg/m 2 ) received enoxaparin 40 mg Q12H, while those with a BMI >50 kg/m 2 (n = 99, average BMI 57.4 kg/m 2 ) received enoxaparin 60 mg Q12H during hospitalization. Enoxaparin dosing was changed to once daily administration on discharge and continued for 10 days. Anti-Xa levels were monitored 4 hours after the third dose, and dose adjustments were made by 10 mg for levels outside of the range 0.18 to 0.44 IU/mL. Seventy-four percent of the patients in both groups achieved targeted prophylactic anti-Xa levels after the third dose. Significant bleeding occurred in 2.24% of patients (n = 5), with 1.79% (n = 4) of patients requiring transfusion, and one requiring reoperation. All patients with significant bleeding received the 40 mg enoxaparin dose. Anti-Xa levels that were above the targeted range occurred more frequently in the 60 mg group than in the 40 mg group (7.8% vs 0%), but no analysis of statistical significance was provided. Only one patient in the study developed nonfatal VTE; this patient was prescribed a 40-mg dose. Bleeding was not associated with the supratherapeutic anti-Xa levels. The authors concluded that higher enoxaparin (40 mg Q12H or 60 mg Q12H) dosing in patients with a BMI ≤50 kg/m 2 and ≥50 kg/m 2 provided effective prophylaxis, is well tolerated, and did not increase the risk for bleeding in patients undergoing gastric bypass. This study provides data that enoxaparin 40 mg Q12H or 60 mg Q12H may be safe and effective in patients with BMI ≥40 kg/m 2 .
Rondina et al evaluated the efficacy of weight-based approach to dosing enoxaparin for the prophylaxis of VTE in 28 medically ill patients with BMI ≥35 kg/m 2 . 18 Baseline characteristics included an average age of 54.7 ± 11.2 years, weight of 135.6 ± 25.3 kg, and BMI of 48.1 ± 11.1 kg/m 2 . Patients received 0.5 mg/kg subcutaneously once daily for 2 days with peak anti-Xa levels obtained 4 to 6 hours after administration of the first or second dose of enoxaparin. The sensitivity of the anti-Xa assay range was defined as 0.2 to 2 IU/mL. An average daily dose of enoxaparin was 67 mg (±12 mg), with average peak anti-Xa level of 0.25 units/ mL (SD ± 0.11 IU/mL, range 0.08-0.59 IU/mL). This average anti-Xa level was within the recommended range for thromboprophylaxis, and no patients achieved the therapeutic range of anti-Xa level of 0.6 to 2.0 IU/mL. No bleeding events, symptomatic deep venous thromboembolism (DVT) or pulmonary embolism, or significant thrombocytopenia occurred. The authors concluded that weight-based dosing of enoxaparin 0.5 mg/kg subcutaneously produced anti-Xa near the targeted range for thromboprophylaxis. This study further supports the safety and efficacy of weight-based enoxaparin prophylactic dosing rather than fixed-dose prophylactic dosing in obese patients. However, this study does not inform clinicians as to the long-term safety and effectiveness of this approach.
Simone et al evaluated the pharmacokinetics of enoxaparin 40 mg Q12H (n = 24; BMI 48.8 ± 6.6 kg/m 2 ) compared with 60 mg Q12H (n = 16; BMI 47.3 ± 6.6 kg/m 2 ) in a prospective nonrandomized cohort study of obese patients after bariatric surgery. 19 Patients received enoxaparin 40 mg Q12H (n = 24) or 60 mg Q12H (n = 16) for VTE prophylaxis. All patients had anti-Xa levels obtained 4 hours after the first and third doses. The goal anti-Xa range was defined as 0.18 to 0.44 IU/mL. After the first dose, anti-Xa levels were lower in patients receiving enoxaparin 40 mg Q12H than those receiving 60 mg Q12H (mean 0.17 IU/mL vs 0.26 IU/mL, P < .005). Similar results were observed when comparing the anti-Xa level achieved after the third dose (mean 0.21 IU/mL vs 0.43 IU/mL, P < .001). However, on average the enoxaparin 40 mg group continued to have some subtherapeutic anti-Xa levels whereas the enoxaparin 60 mg Q12 hours did not (44% vs 0%; P = .02). In contrast, 57% of patients receiving 60 mg Q12H had a supratherapeutic anti-Xa after the third dose (maximum = 0.54 IU/ mL). No incidents of bleeding were noted by the investigators. In conclusion, enoxaparin 60 mg Q12H was statistically superior to 40 mg Q12H and achieved therapeutic anti-Xa levels for VTE prevention after bariatric surgery.
A randomized, open label, 2-way crossover study compared weight-based prophylactic dosage in 24 healthy obese patients (average weight = 99.6 ± 15.5 kg; BMI = 30-40 kg/ m 2 ) and 25 healthy nonobese volunteers (average weight = 65.9 ± 9.1; BMI = 18-25 kg/m 2 ). 20 All patients received 2 different regimens of enoxaparin: 1.5 mg/kg/daily for 4 days and in a single 6-hour infusion (1.5 mg/kg), with sequence of these randomized. All patients had ≥7 day washout period. Anti-Xa, anti-IIa activity, and activated partial thromboplastin time (aPTT) levels were obtained from blood samples. On day 1, a higher exposure [AUC and AUC (0-τ) ] of anti-Xa occurred and was statistically significant in obese volunteers compared to nonobese volunteers (14% vs 13%, P = .006, P = .007, respectively) and increased to 19% versus 16% by day 4, which was also statistically significant (P = .002 and P = .001, respectively). Anti-IIa activity was similar between both groups. Time to peak was longer in the obese volunteers compared to nonobese volunteers for both anti-Xa and anti-IIa activity on day 4. Per visual comparison, steady state was reached after the second dose of enoxaparin in nonobese volunteers, whereas it was reached after the third dose of enoxaparin in obese volunteers. No difference was observed in anti-Xa levels between the nonobese and obese patients (1.563 IU/mL vs 1.488 IU/mL, P = not significant). This finding suggests that enoxaparin does not need to be dose adjusted in obese patients receiving weight-based dosing. The investigators also found that obese patients have a lower lean body mass, which lowers the production of anti-Xa during the initial portion of treatment and acknowledged that another marker of anticoagulation besides anti-Xa may be needed in obese patients. This study's conclusion does not align with previous trial information; however, limitations to this trial include a very small sample size.
Effectiveness. Scholten et al evaluated the efficacy of 30 mg subcutaneously of enoxaparin (n = 92; BMI = 51.7 kg/m 2 ) every 12 hours to 40 mg subcutaneously (n = 389; BMI = 50.3 kg/m 2 ) every 12 hours after bariatric surgery in a prospective nonrandomized cohort study. 21 Baseline characteristics included average age of 43.7 to 44.3 years and BMI of 50.4 to 51.7 kg/m 2 . Baseline weight was not defined. Both groups also received nonpharmacologic DVT prophylaxis (ie, early ambulation, graded compression stockings, and intermittent pneumatic compression devices or sequential compression devices). Two hours prior to surgery enoxaparin was administered and continued every 12 hours until fully ambulatory or hospital discharge. Primary outcome measures of complications of venous thrombosis were defined as DVT on ultrasound or venogram, pulmonary embolism on spiral computed tomography scan, and bleeding requiring surgery or change in therapy with transfusion. Of note, current practice standards utilize symptomatic VTE rather than ultrasound surveillance. Enoxaparin 40 mg Q12H was associated with a significant reduction in nonfatal VTE (0.6% vs 5.4%; P < .01). The risk of bleeding was also not found to be increased with enoxaparin 40 mg Q12H as both groups had one incidence of bleeding each (P = not significant). The authors suggested using higher enoxaparin VTE prophylaxis dosing for obese patients.
Wang et al compared the efficacy of high-dose thromboprophylaxis with standard thromboprophylaxis dose using enoxaparin and UFH in obese patients (weight >100 kg and BMI ≥40 kg/m 2 ) in a retrospective cohort study. 22 Baseline characteristics of patients included an average age of 54 to 57 years, weight between 118.6 and 119 kg, and BMI 38.7-39.6 kg/m 2 . They defined high-dose thromboprophylaxis as UFH 7500 units thrice a day or enoxaparin 40 mg twice a day. Standard thromboprophylaxis dosing was considered 5000 units for UFH and morbid obesity was defined as weight >100 kg and BMI ≥40 kg/m 2 . Among morbidly obese inpatients (n = 3928), high-dose thromboprophylaxis (0.77%) decreased the risk of symptomatic VTE compared to standard dosing (1.48%; OR = 0.52; 95% CI = 0.27-1.00; P = .05), but this difference was not statistically significant. Bleeding risk was not increased in high-dose thromboprophylaxis (OR = 0.84; 95% CI = 0.66-1.07; P = .15). The authors then concluded that high-dose thromboprophylaxis is safe and effective in obese patients.
Safety. Singh et al retrospectively evaluated the safety and effectiveness of BMI-based dosing as preoperative prophylaxis. 23 Baseline characteristics included an average age of 43 years, with average BMI of 47.8 ± 6.9 kg/m 2 . One-hundred seventy patients who received Roux-en-Y gastric bypass surgery were divided into respective BMI groups and were assigned to receive weight-based dosing: BMI <40 kg/m 2 : 30 mg twice a day (n = 11); BMI 41 to 49 kg/m 2 : 40 mg twice a day (n = 145); BMI 50 to 59 kg/m 2 : 50 mg twice a day (n = 9); and BMI >59 kg/m 2 : 60 mg twice a day (n = 5). No clinically significant VTE events were reported during hospitalization or during a 2-year followup. There were 5 patients (2.9%) who had nonfatal bleeding complications postoperatively. Four of the 5 patients received 40 mg Q12H. The findings of Singh et al further supports the efficacy of BMI-based preoperative dosing of enoxaparin in prevention of VTE prophylaxis in bariatric surgery patients with a BMI of 41 to 49 kg/m 2 . However, the amount of confidence placed in these results must be tempered due to the low numbers of patients in every BMI group except the BMI 41 to 49 kg/m 2 group.
Summary. In conclusion, the pharmacokinetic, effectiveness, and safety data suggest that increased enoxaparin doses are needed for obese adults. However, there are numerous approaches without a head to head comparison to determine the optimal adjustment. For now, we recommend using 40 mg twice daily as this is a common approach used in the studies documenting the improved effectiveness of higher doses in obese patients (BMI ≥40 kg/m 2 ), without further adverse outcomes.
Dalteparin
Anti-Xa Pharmacokinetics. A retrospective trial by Simoneau et al evaluated morbidly obese patients (n = 135) receiving dalteparin 7500 IU daily during the postoperative period after bariatric surgery to understand the postoperative effects of dalteparin on anti-Xa in this population. 24 Baseline characteristics included an average age of 43.9 ± 10.2 years, weight 148.8 ± 31.2 kg, and BMI 53.7 ± 8.6 kg/m 2 . Four hours after the fourth dalteparin dose postsurgery, anti-Xa levels were measured from each patient. Only 60% of patients reached the targeted prophylactic anti-Xa levels of 0.2 to 0.5 UI/mL. A Tukey-Kramer post hoc analysis showed that increased body weight is correlated with subtherapeutic anti-Xa levels (P = .031). The authors suggested that dalteparin 7500 IU is appropriate for this population, but may not provide a sufficient dose for patients with a very high body weight.
Efficacy. In the retrospective subgroup analysis of the PRE-VENT trial (Prospective Evaluation of Dalteparin Efficacy for Prevention of VTE in Immobilized Patients) by Kucher et al, the efficacy of dalteparin in 1118 medically ill obese patients was compared to efficacy in 2563 medically ill nonobese patients. 25 Obesity was defined for men with a BMI ≥30 kg/m 2 and women with a BMI ≥28.6 kg/m 2 . Baseline characteristics were not matched and included an average weight of 90.8 ± 16.6 kg and BMI 33.8 ± 4.9 kg/m 2 in the obese group, with weight of 68.4 ± 13.5 kg and BMI 24.6 ± 3.8 kg/m 2 in the nonobese group. Average age was not defined. In this study, patients were randomized to receive either dalteparin 5000 IU daily or placebo. The primary end point was a composite of symptomatic VTE, fatal pulmonary embolism, sudden death, or asymptomatic proximal DVT by day 21. There was no difference in the incidence of the primary endpoint between obese (2.8%; 95% CI = 1.3% to 4.3%) and nonobese (4.3%; 95% CI = 2.5% to 6.2%) patients (RR = 0.64; 95% CI = 0.32-1.38), and dalteparin was not associated with an increase in major hemorrhage. However, the study did not include any patients with a BMI ≥40 kg/m 2 . The authors concluded that the efficacy and safety of a fixed low dose of dalteparin (5000 IU daily) is not influenced by BMI in preventing VTE in the obese population.
Summary. The data suggest that no dosing adjustment is required for dalteparin in patients with a BMI <40 kg/m 2 . However, effectiveness data in class III obese (BMI ≥40 kg/ m 2 ) patients is needed to determine if a dosing adjustment is needed.
Tinzaparin
Anti-Xa Pharmacokinetics. Hainer et al evaluated weightbased dosing of tinzaparin in 37 obese patients (weight = 101-165 kg; BMI = 26-61 kg/m 2 ). 26 Baseline characteristics included an average age of 35.4 years, weight of 129.6 kg, and BMI of 43 kg/m 2 . The study compared the pharmacodynamics of therapeutic (175 IU/kg) and prophylactic (75 IU/kg) doses of tinzaparin in this population. The prophylactic dosage of 75 IU/kg produced similar anti-Xa levels in nonobese (0.87 IU/mL; 95% CI = 0.784-0.956) and obese (0.81 IU/mL; 95% CI = 0795-0.859) patients. The findings of this study suggest that weight-based dosing of tinzaparin based on total body weight is appropriate without an absolute maximum dose.
Practitioners targeting anti-Xa levels can use weightbased dosing tinzaparin in patients who weigh <166 kg. However, this approach should not be considered standard medical practice until data are available regarding the safety and effectiveness of a weight-based dosing approach in obese patients.
Discussion
LMWHs are ideal agents for VTE thromboprophylaxis in most patients. However, it is imperative to consider if currently recommended fixed dosages of LMWHs for thromboprophylaxis are appropriate in obese patients. Current evidence available focuses on the use of enoxaparin with only a few studies evaluating dalteparin and tinzaparin.
Of the trials reviewed, there is conflicting consensus on the implication of higher dose enoxaparin to treat or prevent thrombosis in the obese population and the necessary dose increase to prevent thrombosis. The studies that suggest that a higher LMWH dosage is needed for these patients either proposed a higher fixed dosing, weight-based dosing, BMIbased dosing, or increasing VTE prophylactic doses by 30%. There are benefits by basing the dosage off of BMI; however, few efficacy and safety trials have been completed to fully elucidate this type of regimen. Therefore, BMI dosing is not suggested until further evidence is provided. Based on the studies that are presented in this review, it is appropriate to dose obese patients either with a 30% increase in enoxaparin or by treating with a higher fixed dosing such as 40 mg BID in these patients.
Regarding dalteparin and tinzaparin, large, randomized efficacy trials are not available at this time. Because of insufficient data, it is highly suggested that health care providers refrain from prescribing a higher dose of LMWH in obese patients on these medications.
Since obesity is a risk factor for VTE and is increasing in prevalence, it is imperative that health care providers understand that the current thromboprophylaxis dosing of LMWH may be insufficient to prevent VTE in obese patients.
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